---
title: "野村將翰森製藥集團目標價從 35.47 港元上調至 35.50 港元。"
description: "野村將翰森製藥集團目標價從 35.47 港元上調至 35.50 港元。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/261829498.md"
published_at: "2025-10-20T07:51:52.000Z"
---

# 野村將翰森製藥集團目標價從 35.47 港元上調至 35.50 港元。

野村將翰森製藥集團目標價從 35.47 港元上調至 35.50 港元。

### Related Stocks

- [03692.HK - 翰森制藥](https://longbridge.com/zh-HK/quote/03692.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Nomura Adjusts Hansoh Pharmaceutical Group's Price Target to HK$37.87 From HK$35.50, Keeps at Neutral | Nomura Adjusts Hansoh Pharmaceutical Group's Price Target to HK$37.87 From HK$35.50, Keeps at Neutral | [Link](https://longbridge.com/zh-HK/news/276056784.md) |
| Hansoh Pharmaceutical Says Aumolertinib Mesylate Tablets Approved In EU As Monotherapy | Hansoh Pharmaceutical Group Company Ltd :AUMOLERTINIB MESYLATE TABLETS APPROVED IN EU AS MONOTHERAPY | [Link](https://longbridge.com/zh-HK/news/276401882.md) |
| Hansoh Pharmaceutical Group Company Limited Announces Approval in the European Union as Monotherapy | Hansoh Pharmaceutical Group Company Limited announced that Aumolertinib Mesylate Tablets, known as Ameile in China, rece | [Link](https://longbridge.com/zh-HK/news/276480305.md) |
| Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib | Hansoh Wins EU Approval for Key Lung Cancer Drug Aumolertinib | [Link](https://longbridge.com/zh-HK/news/276393466.md) |
| Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | [Link](https://longbridge.com/zh-HK/news/276056763.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。